Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar

被引：0
|
作者：
Mahmmod, S. [1 ]
Schultheiss, J. P. D. [1 ]
Tan, A. C. I. T. L. [2 ]
Lutgens, M. W. M. D. [3 ]
Gilissen, L. P. L. [4 ]
Mahmmod, N. [5 ]
van der Meulen-de Jong, A. E. [6 ]
Dijkstra, G. [7 ]
van Bodegraven, A. A. [8 ]
Oldenburg, B. [1 ]
Fidder, H. H. [1 ]
机构：
[1] UMC Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands
[2] Canisius Wilhelmina Ziekenhuis, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
[3] Elisabeth TweeSteden Ziekenhuis, Dept Gastroenterol & Hepatol, Tilburg, Netherlands
[4] Catharina Hosp, Dept Gastroenterol & Hepatol, Eindhoven, Netherlands
[5] St Antonius Hosp, Dept Gastroenterol & Hepatol, Nieuwegein, Netherlands
[6] Leiden UMC, Dept Gastroenterol & Hepatol, Leiden, Netherlands
[7] Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[8] Zuyderland Ziekenhuis, Dept Gastroenterol & Hepatol, Sittard, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P326
引用
收藏
页码：S316 / S317
页数：2
相关论文
共 50 条
  • [1] IN PATIENTS WITH IBD SWITCHING FROM ORIGINATOR INFLIXIMAB (REMICADE) TO BIOSIMILAR INFLIXIMAB (CT-P13) IS SAFE AND EFFECTIVE
    Rahmany, S.
    Cotton, S.
    Garnish, S.
    Brown, M.
    Saich, R.
    Lloyd, D.
    Gordon, J. N.
    GUT, 2016, 65 : A89 - A89
  • [2] Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
    Bergqvist, Viktoria
    Kadivar, Mohammad
    Molin, Daniel
    Angelison, Leif
    Hammarlund, Per
    Olin, Marie
    Torp, Jorgen
    Grip, Olof
    Nilson, Stefan
    Hertervig, Erik
    Lillienau, Jan
    Marsal, Jan
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2018, 11
  • [3] EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS
    Privitera, G.
    Pugliese, D.
    Tolusso, B.
    Gremese, E.
    Papa, A.
    Papparella, L. G.
    Gasbarrini, A.
    Rapaccini, G. L.
    Guidi, L.
    Armuzzi, A.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S10 - S11
  • [4] EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF SWITCHING FROM ORIGINATOR INFILIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN A LARGE COHORT OF IBD PATIENTS
    Privitera, Giuseppe
    Pugliese, Daniela
    Tolusso, Barbara
    Gremese, Elisa
    Papa, Alfredo
    Papparella, Luigi Giovanni
    Gasbarrini, Antonio
    Rapaccini, Gian Lodovico
    Guidi, Luisa
    Armuzzi, Alessandro
    GASTROENTEROLOGY, 2020, 158 (06) : S462 - S462
  • [5] Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance
    Scherlinger, Marc
    Germain, Vincent
    Labadie, Celine
    Barnetche, Thomas
    Truchetet, Marie-Elise
    Bannwarth, Bernard
    Mehsen-Cetre, Nadia
    Richez, Christophe
    Schaeverbeke, Thierry
    JOINT BONE SPINE, 2018, 85 (05) : 561 - 567
  • [6] Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease
    Martin-Gutierrez, Nerea
    German Sanchez-Hernandez, Jose
    Rebollo, Noemi
    Pordomingo, Alejandra F.
    Munoz, Fernando
    Jose Otero, Maria
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (04) : 222 - 227
  • [7] SWITCHING FROM INFLIXIMAB ORIGINATOR TO THE BIOSIMILAR (CT-P13) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY ABOUT EFFECTIVENESS AND SAFETY
    Annulli, G.
    Quatraccioni, C.
    Daretti, L. M.
    Antuono, S.
    Guardati, P.
    Calzolari, M.
    Benedetti, A.
    Di Sario, A.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S134 - S135
  • [8] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [9] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [10] A Review of CT-P13: An Infliximab Biosimilar
    Kate McKeage
    BioDrugs, 2014, 28 : 313 - 321
12345